Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 14, 2008

Pfizer Launches New Global Research Unit

  • Pfizer launched an independent research unit known as Pfizer Regenerative Medicine. The unit, led by CSO, Ruth McKernan, Ph.D., is expected to employ around 70 researchers and will build on recent scientific progress in understanding the biology of stem cells. The scientists will operate in small, flexible teams, with the capability to make decisions quickly and effectively.

    Researchers at Pfizer Regenerative Medicine will explore the use of stem cells to develop future treatments that may prevent disability, repair failing organs, and treat degenerative diseases. The ultimate goal will be to deliver new medicinal products that can pave the way for the use of cells as therapeutics.

    Pfizer Regenerative Medicine will be co-located in the biotech hubs of Cambridge, U.K., and Cambridge, MA, in the U.S. The U.K. unit will focus on neural and sensory disorders, and the U.S. site on endocrine and cardiac research.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »